What is Cognition Therapeutics, Inc.'s official website?

Cognition Therapeutics, Inc.'s website is cogrx.com

How many employees are working in Cognition Therapeutics, Inc. right now?

Cognition Therapeutics, Inc. has 41 employees.

What is Cognition Therapeutics, Inc.'s industry?

Cognition Therapeutics, Inc.'s industry is Biotechnology Research

Who are Cognition Therapeutics, Inc.'s top competitors?

Cognition Therapeutics, Inc.'s top competitors are , , , , , ,

Cognition Therapeutics, Inc. company information, Employees & Contact Information

Explore related pages

Cognition Therapeutics, Inc. email format Cognition Therapeutics, Inc. management contacts

Related company profiles:

Cognition Therapeutics, Inc. is a clinical stage company developing oral drugs for neurodegenerative disorders like Alzheimer's disease and dementia with Lewy bodies.

Employees: 41
Founded: -
Address: 2500 Westchester Ave, Purchase,new York 10577,united States
Phone: (412)481-2210
Email: in****@****grx.com
Industry: Biotechnology Research
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)
Website: cogrx.com
Keywords: neuroscience, drug development, clinical research, Alzheimer's disease, Dementia with Lewy bodies, dementia research.
HQ: Purchase, New York
Competitors: BlueSphere Bio, Carmell Cosmetics, Krystal Biotech, Inc., Novasenta, Vertex Pharmaceuticals, Noveome Biotherapeutics, Inc., Spark Therapeutics, Inc., Avista Therapeutics, Imagine Pharma, Peptilogics.

Cognition Therapeutics, Inc. Questions

News

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) - Yahoo Finance

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) Yahoo Finance

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire

$30 Million Funding: Cognition Therapeutics Advances Breakthrough Neurodegenerative Drug to Phase 3 - Stock Titan

$30 Million Funding: Cognition Therapeutics Advances Breakthrough Neurodegenerative Drug to Phase 3 Stock Titan

Breakthrough Alzheimer's Drug Shows 28% Success Rate as Cognition Advances Multiple Clinical Programs - Stock Titan

Breakthrough Alzheimer's Drug Shows 28% Success Rate as Cognition Advances Multiple Clinical Programs Stock Titan

Neurodegenerative Drug Developer Cognition Therapeutics Maintains Nasdaq Listing After Price Recovery - Stock Titan

Neurodegenerative Drug Developer Cognition Therapeutics Maintains Nasdaq Listing After Price Recovery Stock Titan

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs - Yahoo Finance

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs Yahoo Finance

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update GlobeNewswire

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease - Yahoo Finance

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease Yahoo Finance

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - Yahoo Finance

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC Yahoo Finance

Philanthropic Donor Funds Cognition Therapeutics’ Expanded - GlobeNewswire

Philanthropic Donor Funds Cognition Therapeutics’ Expanded GlobeNewswire

Cognition Therapeutics Announces Closing of Public Offering - Yahoo Finance

Cognition Therapeutics Announces Closing of Public Offering Yahoo Finance

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025 - GlobeNewswire

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025 GlobeNewswire

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock - GlobeNewswire

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock GlobeNewswire

Cognition Therapeutics to Present Preclinical Results - GlobeNewswire

Cognition Therapeutics to Present Preclinical Results GlobeNewswire

Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO - PR Newswire

Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO PR Newswire

Companies like Cognition Therapeutics, Inc.

Top Cognition Therapeutics, Inc. Employees

Steven A. Weissman

Vice President, Head Of Cmc At Cognition Therapeutics

Short Hills, New Jersey, United States, United States

View

5
gmail.com, gmail.com, verizon.net, lexpharma.com, cogrx.com
Amanda Carber

n/a

Pompano Beach, Florida, United States, United States

View

5
kpslife.com, comcast.net, aol.com, adelphia.net, aol.com

9 +126790XXXXX
Jennifer Iaci

Vice President Of Development Operations

Montville, New Jersey, United States, United States

View

6
hotmail.com, acorda.com, aol.com, excite.com, ovidrx.com, cogrx.com

4 +197340XXXXX
Gilbert M. Rishton

Cso At Cardax / Co-Founder And Chief Chemistry Advisor At Cognition Therapeutics / Drug Development, Los Angeles

Los Angeles, California, United States, United States

View

5
gmail.com, gmail.com, csuci.edu, cogrx.com, cardaxpharma.com

3 +131092XXXXX

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Cognition Therapeutics, Inc. company information, Employees & Contact Information

Explore related pages

Company Details

Cognition Therapeutics, Inc. Questions

What is Cognition Therapeutics, Inc.'s helpline number?

What is Cognition Therapeutics, Inc.'s official website?

What is Cognition Therapeutics, Inc.'s LinkedIn profile?

How many employees are working in Cognition Therapeutics, Inc. right now?

What is Cognition Therapeutics, Inc.'s industry?

What are Cognition Therapeutics, Inc.'s top competitors?

What is Cognition Therapeutics, Inc.'s support email address?

What are Cognition Therapeutics, Inc.'s categories?

When was Cognition Therapeutics, Inc. founded?

News

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) - Yahoo Finance

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire

$30 Million Funding: Cognition Therapeutics Advances Breakthrough Neurodegenerative Drug to Phase 3 - Stock Titan

Breakthrough Alzheimer's Drug Shows 28% Success Rate as Cognition Advances Multiple Clinical Programs - Stock Titan

Neurodegenerative Drug Developer Cognition Therapeutics Maintains Nasdaq Listing After Price Recovery - Stock Titan

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs - Yahoo Finance

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease - Yahoo Finance

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - Yahoo Finance

Philanthropic Donor Funds Cognition Therapeutics’ Expanded - GlobeNewswire

Cognition Therapeutics Announces Closing of Public Offering - Yahoo Finance

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025 - GlobeNewswire

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock - GlobeNewswire

Cognition Therapeutics to Present Preclinical Results - GlobeNewswire

Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO - PR Newswire

Companies like Cognition Therapeutics, Inc.

Avista Therapeutics

Novasenta

Noveome Biotherapeut...

Spark Therapeutics, ...

Imagine Pharma

Krystal Biotech, Inc.

Bluesphere Bio

Carmell Cosmetics

Peptilogics

Vertex Pharmaceuticals

Top Cognition Therapeutics, Inc. Employees

Steven A. Weissman

Vice President, Head Of Cmc At Cognition Therapeutics

Amanda Carber

n/a

Jennifer Iaci

Vice President Of Development Operations

Gilbert M. Rishton

Cso At Cardax / Co-Founder And Chief Chemistry Advisor At Cognition Therapeutics / Drug Development, Los Angeles

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data